Sirtex Medical Limited
(ASX:SRX) has completed patient recruitment in the FOXFIRE Global randomised controlled clinical study.
The biotechnology and medical device company says more than 200 patients were recruited globally which came in ahead of expectations.
CEO Gilman Wong says the company is delighted to have completed the recruitment of its FOXFIRE Global clinical study on schedule.
The study is aiming to determine whether SIR-Spheres microspheres, in combination with existing chemotherapy, can increase overall survival in a clinically significant manner in these patients versus chemotherapy alone.
Sirtex Medical reported a net profit of $23.86 million in the 2014 financial year.
